{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:26Z","timestamp":1794047486637,"version":"4.8.0"},"reference-count":69,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Multiple myeloma (MM) patients are often refractory to targeted therapies including proteasome inhibitors. Here, analysis of RNA sequencing data derived from 672 patients with newly diagnosed or relapsed\/refractory disease identified the acid ceramidase, ASAH1, as a key regulator of resistance to proteasome inhibitors. Genetic or pharmacological blockade of ASAH1 remarkably restored sensitivity to proteasome inhibitors and protected mice from resistant MM progression in vivo. Mechanistically, ASAH1 depletion of ceramide promoted SET inhibition of PP2A phosphatase activity, thus facilitating increased expression and activity of the pro-survival proteins, MCL-1 and BCL-2. We corroborated these findings in human MM datasets, and in ex vivo patients\u2019 MM cells. These preclinical studies suggest that ASAH1 may be a potential therapeutic target for the treatment of relapsed\/refractory MM.<\/jats:p>","DOI":"10.3324\/haematol.2024.285587","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T03:41:18Z","timestamp":1733370078000},"page":"1351-1367","source":"Crossref","is-referenced-by-count":2,"title":["Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed\/refractory multiple myeloma"],"prefix":"10.3324","volume":"110","author":[{"given":"Ryan T.","family":"Bishop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praneeth","family":"Sudalagunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl J.","family":"Nyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghunandan R.","family":"Alugubelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Meads","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Frieling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niveditha","family":"Nerlakanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Tauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Koomen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariosto S.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H.","family":"Shain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor C.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"75721","doi-asserted-by":"crossref","unstructured":"Kumar SK, Rajkumar V, Kyle RA. Multiple myeloma. Nat Rev Dis Primers. 2017; 3:17046.","DOI":"10.1038\/nrdp.2017.46"},{"key":"75722","doi-asserted-by":"crossref","unstructured":"Roodman GD. Pathogenesis of myeloma bone disease. J Cell Biochem. 2010; 109(2):283-291.","DOI":"10.1002\/jcb.22403"},{"key":"75723","doi-asserted-by":"crossref","unstructured":"Cowan AJ, Green DJ, Kwok M. Diagnosis and management of multiple myeloma: a review. JAMA. 2022; 327(5):464-477.","DOI":"10.1001\/jama.2022.0003"},{"key":"75724","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Harousseau JL, Durie B. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117(18):4691-4695.","DOI":"10.1182\/blood-2010-10-299487"},{"key":"75725","doi-asserted-by":"crossref","unstructured":"Sonneveld P. Management of multiple myeloma in the relapsed\/ refractory patient. Hematology Am Soc Hematol Educ Program. 2017; 2017(1):508-517.","DOI":"10.1182\/asheducation-2017.1.508"},{"key":"75726","doi-asserted-by":"crossref","unstructured":"Hu J, Hu WX. Targeting signaling pathways in multiple myeloma: pathogenesis and implication for treatments. Cancer Lett. 2018; 414:214-221.","DOI":"10.1016\/j.canlet.2017.11.020"},{"key":"75727","doi-asserted-by":"crossref","unstructured":"Jovanovic KK, Roche-Lestienne C, Ghobrial IM, Facon T, Quesnel B, Manier S. Targeting MYC in multiple myeloma. Leukemia. 2018; 32(6):1295-1306.","DOI":"10.1038\/s41375-018-0036-x"},{"key":"75728","unstructured":"Ghermezi M, Spektor TM, Berenson JR. The role of JAK inhibitors in multiple myeloma. Clin Adv Hematol Oncol. 2019; 17(9):500-505."},{"key":"75729","doi-asserted-by":"crossref","unstructured":"Ramakrishnan V, Kumar S. PI3K\/AKT\/mTOR pathway in multiple myeloma: from basic biology to clinical promise. Leuk Lymphoma. 2018; 59(11):2524-2534.","DOI":"10.1080\/10428194.2017.1421760"},{"key":"75730","doi-asserted-by":"crossref","unstructured":"Oancea M, Mani A, Hussein MA, Almasan A. Apoptosis of multiple myeloma. Int J Hematol. 2004; 80(3):224-231.","DOI":"10.1532\/IJH97.04107"},{"key":"75731","doi-asserted-by":"crossref","unstructured":"Inam S, Ross JA, Touzeau C, Moreau P, Kumar SK, Harrison SJ. Paving the way to precision medicine in multiple myeloma. Expert Rev Hematol. 2021; 14(4):323-327.","DOI":"10.1080\/17474086.2021.1905515"},{"key":"75732","doi-asserted-by":"crossref","unstructured":"Aksoy O, Lind J, Sunder-Plassmann V, Vallet S, Podar K. Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): therapeutic implications. Cytokine. 2023; 161:156062.","DOI":"10.1016\/j.cyto.2022.156062"},{"key":"75733","doi-asserted-by":"crossref","unstructured":"Punnoose EA, Leverson JD, Peale F. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016; 15(5):1132-1144.","DOI":"10.1158\/1535-7163.MCT-15-0730"},{"key":"75734","doi-asserted-by":"crossref","unstructured":"Evangelisti C, Evangelisti C, Buontempo F. Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. Leukemia. 2016; 30(11):2142-2151.","DOI":"10.1038\/leu.2016.208"},{"key":"75735","doi-asserted-by":"crossref","unstructured":"Sentelle RD, Senkal CE, Jiang W. Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat Chem Biol. 2012; 8(10):831-838.","DOI":"10.1038\/nchembio.1059"},{"key":"75736","doi-asserted-by":"crossref","unstructured":"Young MM, Kester M, Wang HG. Sphingolipids: regulators of crosstalk between apoptosis and autophagy. J Lipid Res. 2013; 54(1):5-19.","DOI":"10.1194\/jlr.R031278"},{"key":"75737","doi-asserted-by":"crossref","unstructured":"Mohamed A, Collins J, Jiang H. Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: probing the lipid metabolome. PLoS One. 2020; 15(1):e0227455.","DOI":"10.1371\/journal.pone.0227455"},{"key":"75738","doi-asserted-by":"crossref","unstructured":"Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol. 2018; 19(3):175-191.","DOI":"10.1038\/nrm.2017.107"},{"key":"75739","doi-asserted-by":"crossref","unstructured":"Wallington-Beddoe CT PJ, Tong D, Pitson SM, Bradstock KF, Bendall LJ. Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression. Cancer Res. 2014; 74(10):2803.","DOI":"10.1158\/0008-5472.CAN-13-2732"},{"key":"75740","doi-asserted-by":"crossref","unstructured":"Liang J, Nagahashi M, Kim EY. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 2013; 23(1):107-120.","DOI":"10.1016\/j.ccr.2012.11.013"},{"key":"75741","doi-asserted-by":"crossref","unstructured":"Visentin B, Vekich JA, Sibbald BJ. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell. 2006; 9(3):225-238.","DOI":"10.1016\/j.ccr.2006.02.023"},{"key":"75742","doi-asserted-by":"crossref","unstructured":"Zhang L, Liu X, Zuo Z, Hao C, Ma Y. Sphingosine kinase 2 promotes colorectal cancer cell proliferation and invasion by enhancing MYC expression. Tumour Biol. 2016; 37(6):8455-8460.","DOI":"10.1007\/s13277-015-4700-8"},{"key":"75743","doi-asserted-by":"crossref","unstructured":"Ponnusamy S, Selvam SP, Mehrotra S. Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1\/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO Mol Med. 2012; 4(8):761-775.","DOI":"10.1002\/emmm.201200244"},{"key":"75744","doi-asserted-by":"crossref","unstructured":"Zhuang J, Shirazi F, Singh RK. Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma. Blood. 2019; 133(14):1572-1584.","DOI":"10.1182\/blood-2018-06-859686"},{"key":"75745","doi-asserted-by":"crossref","unstructured":"Chen S, Dai Y, Pei XY. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Res. 2012; 72(16):4225-4237.","DOI":"10.1158\/0008-5472.CAN-12-1118"},{"key":"75746","doi-asserted-by":"crossref","unstructured":"Chen S, Zhang Y, Zhou L. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood. 2014; 124(17):2687-2697.","DOI":"10.1182\/blood-2014-03-564534"},{"key":"75747","doi-asserted-by":"crossref","unstructured":"Cheng JC, Bai A, Beckham TH. Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest. 2013; 123(10):4344-4358.","DOI":"10.1172\/JCI64791"},{"key":"75748","doi-asserted-by":"crossref","unstructured":"Doan NB, Nguyen HS, Montoure A. Acid ceramidase is a novel drug target for pediatric brain tumors. Oncotarget. 2017; 8(15):24753-24761.","DOI":"10.18632\/oncotarget.15800"},{"key":"75749","doi-asserted-by":"crossref","unstructured":"Pizzirani D, Bach A, Realini N. Benzoxazolone carboxamides: potent and systemically active inhibitors of intracellular acid ceramidase. Angew Chem Int Ed Engl. 2015; 54(2):485-489.","DOI":"10.1002\/anie.201409042"},{"key":"75750","doi-asserted-by":"crossref","unstructured":"Vethakanraj HS, Sesurajan BP, Padmanaban VP, Jayaprakasam M, Murali S, Sekar AK. Anticancer effect of acid ceramidase inhibitor ceranib-2 in human breast cancer cell lines MCF-7, MDA MB-231 by the activation of SAPK\/JNK, p38 MAPK apoptotic pathways, inhibition of the Akt pathway, downregulation of ERalpha. Anticancer Drugs. 2018; 29(1):50-60.","DOI":"10.1097\/CAD.0000000000000566"},{"key":"75751","doi-asserted-by":"crossref","unstructured":"Draper JM, Xia Z, Smith RA, Zhuang Y, Wang W, Smith CD. Discovery and evaluation of inhibitors of human ceramidase. Mol Cancer Ther. 2011; 10(11):2052-2061.","DOI":"10.1158\/1535-7163.MCT-11-0365"},{"key":"75752","doi-asserted-by":"crossref","unstructured":"Chavez JA, Holland WL, Bar J, Sandhoff K, Summers SA. Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling. J Biol Chem. 2005; 280(20):20148-20153.","DOI":"10.1074\/jbc.M412769200"},{"key":"75753","doi-asserted-by":"crossref","unstructured":"Bedia C, Casas J, Andrieu-Abadie N, Fabrias G, Levade T. Acid ceramidase expression modulates the sensitivity of A375 melanoma cells to dacarbazine. J Biol Chem. 2011; 286(32):28200-28209.","DOI":"10.1074\/jbc.M110.216382"},{"key":"75754","doi-asserted-by":"crossref","unstructured":"Tan SF, Liu X, Fox TE. Acid ceramidase is upregulated in AML and represents a novel therapeutic target. Oncotarget. 2016; 7(50):83208-83222.","DOI":"10.18632\/oncotarget.13079"},{"key":"75755","doi-asserted-by":"crossref","unstructured":"Yilmaz S, Ayati M, Schlatzer D, Cicek AE, Chance MR, Koyuturk M. Robust inference of kinase activity using functional networks. Nat Commun. 2021; 12(1):1177.","DOI":"10.1038\/s41467-021-21211-6"},{"key":"75756","doi-asserted-by":"crossref","unstructured":"De Palma RM, Parnham SR, Li Y. The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction. FASEB J. 2019; 33(6):7647-7666.","DOI":"10.1096\/fj.201802264R"},{"key":"75757","doi-asserted-by":"crossref","unstructured":"Saddoughi SA, Gencer S, Peterson YK. Sphingosine analogue drug FTY720 targets I2PP2A\/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 2013; 5(1):105-121.","DOI":"10.1002\/emmm.201201283"},{"key":"75758","doi-asserted-by":"crossref","unstructured":"Silva A, Silva MC, Sudalagunta P. An ex vivo platform for the prediction of clinical response in multiple myeloma. Cancer Res. 2017; 77(12):3336-3351.","DOI":"10.1158\/0008-5472.CAN-17-0502"},{"key":"75759","doi-asserted-by":"crossref","unstructured":"Sudalagunta P, Silva MC, Canevarolo RR. A pharmacodynamic model of clinical synergy in multiple myeloma. EBioMedicine. 2020; 54:102716.","DOI":"10.1016\/j.ebiom.2020.102716"},{"key":"75760","doi-asserted-by":"crossref","unstructured":"Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. 2013; 4(12):2186-2207.","DOI":"10.18632\/oncotarget.1497"},{"key":"75761","doi-asserted-by":"crossref","unstructured":"Seiller C, Maiga S, Touzeau C. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX\/BAK heterocomplexes. Cell Death Dis. 2020; 11(5):316.","DOI":"10.1038\/s41419-020-2505-1"},{"key":"75762","doi-asserted-by":"crossref","unstructured":"Barth BM, Shanmugavelandy SS, Tacelosky DM, Kester M, Morad SA, Cabot MC. Gaucher\u2019s disease and cancer: a sphingolipid perspective. Crit Rev Oncog. 2013; 18(3):221-234.","DOI":"10.1615\/CritRevOncog.2013005814"},{"key":"75763","doi-asserted-by":"crossref","unstructured":"Lipchick BC, Utley A, Han Z. The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma. Blood Adv. 2021; 5(7):1933-1946.","DOI":"10.1182\/bloodadvances.2020002578"},{"key":"75764","doi-asserted-by":"crossref","unstructured":"Hengst JA, Dick TE, Sharma A. SKI-178: a multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models. Cancer Transl Med. 2017; 3(4):109-121.","DOI":"10.4103\/ctm.ctm_7_17"},{"key":"75765","doi-asserted-by":"crossref","unstructured":"Venkata JK, An N, Stuart R. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood. 2014; 124(12):1915-1925.","DOI":"10.1182\/blood-2014-03-559385"},{"key":"75766","doi-asserted-by":"crossref","unstructured":"Powell JA, Lewis AC, Zhu W. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. Blood. 2017; 129(6):771-782.","DOI":"10.1182\/blood-2016-06-720433"},{"key":"75767","doi-asserted-by":"crossref","unstructured":"Weigert A, Tzieply N, von Knethen A. Tumor cell apoptosis polarizes macrophages role of sphingosine-1-phosphate. Mol Biol Cell. 2007; 18(10):3810-3819.","DOI":"10.1091\/mbc.e06-12-1096"},{"key":"75768","doi-asserted-by":"crossref","unstructured":"Yao L, Jayasinghe RG, Lee Bh. Comprehensive characterization of the multiple myeloma immune microenvironment using integrated scRNA-seq, CyTOF, and CITE-seq analysis. Cancer Res Commun. 2022; 2(10):1255-1265.","DOI":"10.1158\/2767-9764.CRC-22-0022"},{"key":"75769","doi-asserted-by":"crossref","unstructured":"Sun H, Sun S, Chen G. Ceramides and sphingosine-1-phosphate mediate the distinct effects of M1\/M2-macrophage infusion on liver recovery after hepatectomy. Cell Death Dis. 2021; 12(4):324.","DOI":"10.1038\/s41419-021-03616-9"},{"key":"75770","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Khan I, Chiu C. Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma. Exp Hematol Oncol. 2018; 7:3.","DOI":"10.1186\/s40164-018-0096-7"},{"key":"75771","doi-asserted-by":"crossref","unstructured":"Vaena S, Chakraborty P, Lee HG. Aging-dependent mitochondrial dysfunction mediated by ceramide signaling inhibits antitumor T cell response. Cell Rep. 2021; 35(5):109076.","DOI":"10.1016\/j.celrep.2021.109076"},{"key":"75772","doi-asserted-by":"crossref","unstructured":"Priceman SJ, Shen S, Wang L. S1PR1 is crucial for accumulation of regulatory T cells in tumors via STAT3. Cell Rep. 2014; 6(6):992-999.","DOI":"10.1016\/j.celrep.2014.02.016"},{"key":"75773","doi-asserted-by":"crossref","unstructured":"Chakraborty P, Vaena SG, Thyagarajan K. Pro-survival lipid sphingosine-1-phosphate metabolically programs T cells to limit anti-tumor activity. Cell Rep. 2019; 28(7):1879-1893.e7.","DOI":"10.1016\/j.celrep.2019.07.044"},{"key":"75774","doi-asserted-by":"crossref","unstructured":"von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, Grosveld G. Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3\u2019 half to different genes: characterization of the set gene. Mol Cell Biol. 1992; 12(8):3346-3355.","DOI":"10.1128\/mcb.12.8.3346-3355.1992"},{"key":"75775","doi-asserted-by":"crossref","unstructured":"Adachi Y, Pavlakis GN, Copeland TD. Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. J Biol Chem. 1994; 269(3):2258-2262.","DOI":"10.1016\/S0021-9258(17)42162-4"},{"key":"75776","doi-asserted-by":"crossref","unstructured":"Di Mambro A, Esposito MT. Thirty years of SET\/TAF1beta\/I2PP2A: from the identification of the biological functions to its implications in cancer and Alzheimer\u2019s disease. Biosci Rep. 2022; 42(11):BSR20221280.","DOI":"10.1042\/BSR20221280"},{"key":"75777","doi-asserted-by":"crossref","unstructured":"Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D. Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell. 2001; 104(1):119-130.","DOI":"10.1016\/S0092-8674(01)00196-9"},{"key":"75778","doi-asserted-by":"crossref","unstructured":"Seo SB, Macfarlan T, McNamara P. Regulation of histone acetylation and transcription by nuclear protein pp32, a subunit of the INHAT complex. J Biol Chem. 2002; 277(16):14005-14010.","DOI":"10.1074\/jbc.M112455200"},{"key":"75779","doi-asserted-by":"crossref","unstructured":"Mukhopadhyay A, Saddoughi SA, Song P. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J. 2009; 23(3):751-763.","DOI":"10.1096\/fj.08-120550"},{"key":"75780","doi-asserted-by":"crossref","unstructured":"Arnold HK, Sears RC. A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev. 2008; 27(2):147-158.","DOI":"10.1007\/s10555-008-9128-9"},{"key":"75781","doi-asserted-by":"crossref","unstructured":"Gotz J, Probst A, Mistl C, Nitsch RM, Ehler E. Distinct role of protein phosphatase 2A subunit Calpha in the regulation of E-cadherin and beta-catenin during development. Mech Dev. 2000; 93(1-2):83-93.","DOI":"10.1016\/S0925-4773(00)00267-7"},{"key":"75782","doi-asserted-by":"crossref","unstructured":"Samanta AK, Chakraborty SN, Wang Y. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene. 2009; 28(14):1669-1681.","DOI":"10.1038\/onc.2009.7"},{"key":"75783","doi-asserted-by":"crossref","unstructured":"Resjo S, Goransson O, Harndahl L, Zolnierowicz S, Manganiello V, Degerman E. Protein phosphatase 2A is the main phosphatase involved in the regulation of protein kinase B in rat adipocytes. Cell Signal. 2002; 14(3):231-238.","DOI":"10.1016\/S0898-6568(01)00238-8"},{"key":"75784","doi-asserted-by":"crossref","unstructured":"Carter BZ, Mak PY, Tao W. Maximal activation of apoptosis signaling by cotargeting antiapoptotic proteins in BH3 mimetic-resistant AML and AML stem cells. Mol Cancer Ther. 2022; 21(6):879-889.","DOI":"10.1158\/1535-7163.MCT-21-0690"},{"key":"75785","doi-asserted-by":"crossref","unstructured":"Yi X, Sarkar A, Kismali G. AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia. Clin Cancer Res. 2020; 26(14):3856-3867.","DOI":"10.1158\/1078-0432.CCR-19-1397"},{"key":"75786","doi-asserted-by":"crossref","unstructured":"Tan SF, Dunton W, Liu X. Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-kappaB-dependent P-glycoprotein upregulation. J Lipid Res. 2019; 60(6):1078-1086.","DOI":"10.1194\/jlr.M091876"},{"key":"75787","doi-asserted-by":"crossref","unstructured":"White-Gilbertson S, Lu P, Norris JS, Voelkel-Johnson C. Genetic and pharmacological inhibition of acid ceramidase prevents asymmetric cell division by neosis. J Lipid Res. 2019; 60(7):1225-1235.","DOI":"10.1194\/jlr.M092247"},{"key":"75788","doi-asserted-by":"crossref","unstructured":"Lai M, Amato R, La Rocca V. Acid ceramidase controls apoptosis and increases autophagy in human melanoma cells treated with doxorubicin. Sci Rep. 2021; 11(1):11221.","DOI":"10.1038\/s41598-021-90219-1"},{"key":"75789","doi-asserted-by":"crossref","unstructured":"Malvi P, Janostiak R, Nagarajan A, Zhang X, Wajapeyee N. N-acylsphingosine amidohydrolase 1 promotes melanoma growth and metastasis by suppressing peroxisome biogenesis-induced ROS production. Mol Metab. 2021; 48:101217.","DOI":"10.1016\/j.molmet.2021.101217"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11859\/77870","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11859\/78417","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11859\/77870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:48Z","timestamp":1794046068000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":69,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285587","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,5]]}}}